Logo

Genentech Signs a Worldwide License Agreement with Relay Therapeutics to Develop and Commercialize RLY-1971

Share this

Genentech Signs a Worldwide License Agreement with Relay Therapeutics to Develop and Commercialize RLY-1971

Shots:

  • Relay to receive $75M as upfront- $25M in additional near-term payments- and has the right to opt for 50/50 profit/cost-sharing on RLY-1971 in the US. If Relay exercises the option- it will be eligible to receive 50% profits on US sales & ~$410M as commercialization milestones & royalties on ex-US sales
  • If Relay elects not to opt-in- then it will receive ~$695M as milestones along with royalties on global sales of RLY-1971
  • Genentech will assume the development of RLY-1971 with the potential to expand into multiple combination studies including its GDC-6036 (KRAS G12C inhibitor). The relay will receive additional royalties on the approval of IRLY-1971 + GDC-6036

 ­ Ref: GlobeNewswire | Image: Fierce Biotech

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions